Enterin is the first company in the world to develop a novel drug that repairs the dysfunctional gut-brain axis in patients with neurodegenerative disease
View all
Cytodyn
Vancouver, United States · Post IPO Equity
Regeneron
Tarrytown, United States · Post IPO Equity
Verve Therapeutics
Cambridge, United States · IPO
Biogen
Cambridge, United States
Pionyr Immunotherapeutics
South San Francisco, United States · Corporate Round
Helix
San Mateo, United States · Series C
Guardant Health
Redwood City, United States · Venture
miR Scientific
New York, United States
Genentech
South San Francisco, United States · Venture
Illumina
San Diego, United States
Scipher Medicine
Waltham, United States · Series D
Natera
Austin, United States · Post IPO Equity